The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
PRIMO 2023 | Overcoming resistance to immune checkpoint inhibitors in NSCLC
Luis Raez, MD, FACP, FCCP, Memorial Healthcare System, Pembroke Pines, FL, describes treatment strategies for patients with non-small cell lung cancer (NSCLC), who have progressed on immune checkpoint inhibitors (ICIs). Whilst current options, including docetaxel and ramucirumab, are ineffective, novel targets such as CTLA-4 and TIGIT represent promising treatment strategies. Antibody-drug conjugates (ADCs) and sitravatinib are additional therapies that have provided encouraging results, and the use of adjuvant interleukins can enhance immune responses. This interview took place at the Practical Recommendations in Immuno and Molecular Oncology (PRIMO) 2023 Congress in Honolulu, HI.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
